http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
하정훈,정은정,노동환,권성근,성명훈,김광현,Jeong-Hun Hah,M.D.,Eun-jung Jung,M.D.,Dong Hwan Roh,M.D.,Seong Keun Kwon,M.D.,Myung-Whun Sung,M.D. and Kwang Hyun Kim,M.D. 대한갑상선-내분비외과학회 2004 The Koreran journal of Endocrine Surgery Vol.4 No.2
Purpose: Well differentiated thyroid carcinomas are mostly curable diseases. Invasion of aerodigestive tract by thyroid carcinoma is rare. However, it is considered as a poor prognostic indicator of survival. Some studies showed that local invasion of thyroid carcinoma was the cause of death in many patients. Therefore, adequate local control of the tumor is critical to avoid the mortality as well as the morbidity of the disease. To find proper and adequate treatment modality of locally invasive thyroid carcinoma, we evaluated treatment modalities and outcomes in the patients with thyroid carcinoma with invasion of aerodigestive tract. Methods: Forty patients with thyroid carcinoma invading aerodigestive tract who were treated from July 1989 through July 2002 were reviewed retrospectively. Results: Direct intraluminal invasion of the thyroid carcinoma requires definitive resection of the aerodigestive tract. In case that the extent of tumor was thought to be limited to perichondrium or extraluminal invasion, tracheal shaving procedure was performed. Five-year and 10-year local control rates were 81.6% and 57.4%, respectively. Disease-specific survival rates of 5-year and 10-year were 90.1% and 81.1%, respectively. Conclusion: For the successful treatment of invasive thyroid carcinoma, the resection of the functional structures or the aerodigestive tract should be determined prudently according to the presence of the intraluminal invasion. (Korean J Endocrine Surg 2004;4:101-105)
( Jeong Heo ),( Yoon Jun Kim ),( Jin-woo Lee ),( Ji Hoon Kim ),( Young-suk Lim ),( Kwang-hyub Han ),( Sook-hyang Jeong ),( Mong Cho ),( Ki Tae Yoon ),( Si Hyun Bae ),( Eric D. Crown ),( Linda M. Fredr 대한간학회 2021 Gut and Liver Vol.15 No.6
Background/Aims: Glecaprevir/pibrentasvir (G/P) is the first pan-genotypic direct-acting antiviral combination therapy approved in Korea. An integrated analysis of five phase II and III trials was conducted to evaluate the efficacy and safety of G/P in Korean patients with chronic hepatitis C virus (HCV) infection. Methods: The study analyzed pooled data on Korean patients with HCV infection enrolled in the ENDURANCE 1 and 2, SURVEYOR II part 4 and VOYAGE I and II trials, which evaluated the efficacy and safety of 8 or 12 weeks of G/P treatment. The patients were either treatment-naïve or had received sofosbuvir or interferon-based treatment. Efficacy was evaluated by assessing the rate of sustained virologic response at 12 weeks posttreatment (SVR12). Safety was evaluated by monitoring adverse events (AEs) and laboratory assessments. Results: The analysis included 265 patients; 179 (67.5%) were HCV treatment-naïve, and most patients were either subgenotype 1B (48.7%) or 2A (44.5%). In the intention-to-treat population, 262 patients (98.9%) achieved SVR12. Three patients did not achieve SVR12: one had virologic failure and two had non-virologic failures. Most AEs were grade 1/2; eight patients (3.0%) experienced at least one grade ≥3 AE. No serious AEs related to G/P treatment were reported, and grade ≥3 hepatic laboratory abnormalities were rare (0.8%). Conclusions: G/P therapy was highly efficacious and well tolerated in Korean patients with HCV infection, with most patients achieving SVR12. The safety profile was comparable to that observed in a pooled analysis of a global pan-genotypic population of patients with HCV infection who received G/P. (Gut Liver 2021;15:895-903)
Aging Study with High-Level Radiation Sources for the CMS Forward RPCs
김현철,이경세,Byun Il Kim,홍병식,Chong Kim,D. H. Moon,Duk Gil Koo,E. Won,J. K. Lim,Ji Hyun Kim,Jun Tak Rhee,K. B. Lee,Kwang-Souk Sim,M. S. Ryu,Rong Jiang Hu,S. K. Nam,Sang Yeol Bahk,이석재,Seong Jong Hong,Sung Hw 한국물리학회 2008 THE JOURNAL OF THE KOREAN PHYSICAL SOCIETY Vol.52 No.3
An aging study with intensive radiation sources was performed for the forward resistive plate chambers (RPCs) of the Compact Muon Solenoid (CMS) detector in the Large Hadron Collider experiment (LHC). The expected rate of the radiation background to be induced in the forward RPCs ranges from a few tens of Hz/㎠ to as much as ~1 kHz/㎠. Therefore, the radiation hardness for the forward RPCs should be sufficient to ensure the safe operation of the CMS and successful achievement of the LHC physics. Two oil-coated and one plain double-gap RPCs were manufactured and tested with the neutron beam provided by the MC50 cyclotron of the Korea Institute of Radiological and Medical Science (KIRAMS) and with gamma rays from a 200-mCi137Cs source. The estimated radiation dose induced by the fast neutrons was approximately 50 Gy. No significant aging effect was found to be a consequence of the neutron irradiation, However, a degradation of the RPC performance was observed after intense gamma irradiation for a total of 32.5 days. The mean gamma-signal rate drawn in each RPC was 4.0 kHz/㎠, which was approximately two times the maximum rate expected in the highest η-region covering the particle trigger. Increases in the noise rates and the currents accounted for the degradation in the efficiencies for the RPCs. As a result, safe operation of the forward RPCs in the avalanche mode was ensured for signal rates up to 2 kHz/㎠.